Rocket Pharmaceuticals(US:RCKT) Prnewswireยท2025-07-29 21:06Core Viewpoint - Rocket Pharmaceuticals is facing a class action lawsuit for allegedly concealing safety concerns related to its RP-A501 trial, which has resulted in significant investor losses [1][2]. Company Overview - Rocket Pharmaceuticals is based in Cranbury, New Jersey, and focuses on research and clinical programs in genetic medicine [2]. Legal Issues - The lawsuit claims that Rocket Pharmaceuticals failed to disclose the introduction of a new immunomodulatory agent in the RP-A501 protocol before a patient experienced a fatal adverse event [2]. - Following the announcement of an FDA clinical hold, Rocket Pharmaceuticals' stock price declined nearly 37% over two trading days [2]. Class Action Details - Individuals who purchased Rocket Pharmaceuticals securities from September 17, 2024, to May 26, 2025, may be eligible to join the class action [3]. - The deadline to file for lead plaintiff status is August 11, 2025 [3].